Previous 10 | Next 10 |
2023-03-30 07:40:40 ET GSK ( NYSE: GSK ) and New Jersey-based biotech SCYNEXIS ( NASDAQ: SCYX ) announced an exclusive license agreement on Thursday for Brexafemme (ibrexafungerp tablets), an FDA-approved treatment for certain fungal infections. In the pre-market, ...
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasis SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties SCYNEXIS retains ri...
2023-03-24 08:40:44 ET FiscalNote ( NOTE ) -16% . DiamondHead ( DHHC ) -16% . Rekor Systems ( REKR ) -13% on $10M stock offering . Deutsche Bank ( DB ) -11% as cost of default insurance spikes . Jaguar Health ( JAGX ) -11% ...
2023-03-22 10:27:20 ET A rare and often deadly fungal species is fast spreading across the U.S., infectious-disease specialists have warned. The fungus, a type of yeast called Candida auris , first detected about 15 years ago in Japan, has made a comeback in the U.S., accounting...
2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% . Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...
2023-03-22 08:21:40 ET 89bio ( ETNB ) +50% on topline data for NASH candidate. GameStop ( GME ) +48% on Q4 earnings. Telesis Bio ( TBIO ) +17% on Q4 earnings. Pyxis Oncology ( PYXS ) +11% on Q4 earnings. Ollie's Bargain O...
2023-03-21 10:03:51 ET Gainers: ImmunityBio ( IBRX ) +21% . NuCana ( NCNA ) +16% . Seres Therapeutics ( MCRB ) +14% . SCYNEXIS ( SCYX ) +13% . Corbus Pharmaceuticals ( CRBP ) +12% . Losers: Altimmune ( ALT ) ...
Gainers: Reata Pharmaceuticals ( RETA ) +175% . OncoSec Medical ( ONCS ) +94% . B&G Foods ( BGS ) +30% . Nerdy ( NRDY ) +29% . SCYNEXIS ( SCYX ) +29% . Blackboxstocks ( BLBX ) +29% . Red Robin Gourmet Burgers ( RRGB ...
Scynexis ( NASDAQ: SCYX ) jumped ~23% in the morning hours Wednesday, marking the sharpest intraday gain since Nov. 2021 after Guggenheim launched its coverage with a Buy rating and an $8 per share target citing the potential of its antifungal treatment Brexafemme. In December, th...
Summary Scynexis has performed terribly during 2022 due to continued disappointment in earnings and sales ramp. New labels, including black-boxed warnings, could further hamper the slow commercial adoption of VVC indication, especially in the retail setting. We do not believe rVVC w...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...